FDA Approves IceCure's Post-Marketing Study Design for ProSense® Breast Cancer Treatment

summarizeSummary

IceCure Medical announced that the U.S. FDA has approved the study design for its "ChoICE Trial Post-Market Study" for ProSense® cryoablation in low-risk breast cancer, a crucial step for commercial expansion and data generation.

check_boxKey Events

• FDA Approves Post-Marketing Study Design

  The U.S. FDA approved the study design for the "ChoICE Trial Post-Market Study" for ProSense® cryoablation in the local treatment of low-risk breast cancer. This study was requested by the FDA in connection with the marketing authorization granted in October 2025.

• Study to Support Commercial Expansion

  The study is expected to enroll approximately 400 patients across 30 U.S. clinical sites within 36 months. Participating sites will also serve as active commercial sites, providing cryoablation to patients outside of the study, thereby supporting the Company's commercial expansion.

• Reimbursement and Physician Engagement

  Study procedures are eligible for reimbursement under an established CPT Category III code, which provides approximately $4,000 for the facility fee. IceCure reports strong interest and engagement from leading medical institutions to participate in the study.

auto_awesomeAnalysis

This FDA approval of the post-marketing study design is a significant positive development for IceCure Medical. It allows the company to proceed with the required surveillance study following the October 2025 marketing authorization for ProSense® in low-risk breast cancer. The study, which will enroll approximately 400 patients across 30 U.S. clinical sites, is designed not only to generate real-world data but also to facilitate commercial expansion, as participating sites will also serve as active commercial centers. This move, combined with existing reimbursement codes and supportive ASBrS guidelines, positions IceCure to broaden access to its minimally invasive treatment option. Investors should monitor the commencement of patient enrollment and the progress of the study as it directly impacts the commercial rollout of ProSense®.